2023summer

Cybernics initiatives have started
at the KING SKYFRONT!

（Cybernics Medical Innovation Base Tower A）

In January 2023, CYBERDYNE operation of Cybernics Medical Innovation Base Tower A began.
We interviewed Dr. Yoshiyuki Sankai, President and CEO of CYBERDYNE Inc., known for its businesscentered on cutting-edge Cybernics Technology such as Wearable Cyborg HAL. We asked what CYBERDYNE
is trying to achieve in KING SKYFRONT.
Aim of entering KING SKYFRONT“Promote and develop new medical technology throughregenerative medicine and drug discovery utilizingCybernics technology (Fusion composite technologies
that combine bio/medical systems with AI, robots, andinformation systems) for the fifth industrial revolution.”（Dr. Sankai）Many people think our company is a techcompany, so they may wonder why we are entering KINGSKYFRONT. It is because we have also worked on
pioneering the field of regenerative medicine, such as cell
culture.
Cybernics is a new field combining “Human” + “Cyberphysical space”. To realize "Cybernics Medical HealthInnovation" for people and society, we will create a new"Cybernics Industry" following the robotics and ITindustries. We will also work to realize a "Techno Peer
Support Society" where people and technology coexist andmutually support each other. These initiatives to pioneer
the future will also be the primary initiatives toward thefifth industrial revolution. "Human" initiatives in thecontext of KING SKYFRONT would be initiatives related
to biotechnology and medicine. Therefore, we will
promote initiatives utilizing Cybernics Technology as"technologies that fuse and combine bio/medical systems
with AI, robots, and information systems.”.

We have been working on cell culture for 17 years andhave been presenting the results internationally to interact
with professionals in the field of regenerative medicine.
CYBERDYNE conducts research and development,commercialization, and international expansion of various
fields from biotechnology, medical technology, sensing
technology, robots, data accumulation/analysis/AIprocessing, data linkage, and our Cloud system called CCloud. The opening of Cybernics Medical Innovation Base
Tower A means that partnerships and collaborations withrelated companies will become even more activated andaccelerated.
Now, “formation of co-creation space'' and “Cybernics
innovation'' have started to go forward in this place. It will
also serve as a hub for interdisciplinary fusion.

（Yoshiyuki SANKAI, Ph.D. President & CEO）

In regenerative medicine, the topic of "CybernicTreatment" with the world's first Wearable Cyborg HAL
is starting to become a popular topic of discussion. A
combination of regenerative medicine treatment andCybernic Treatment could become the next phase of thisinnovation. We conducted a post-marketing surveillance
study on a combination treatment using HAL and thelatest nucleic acid medicine for four years. This research
confirmed a remarkable therapeutic effect that had neverbeen seen before. We also have a new-generation
robotized bioreactor that we can provide to the personnel
we will collaborate with at KING SKYFRONT. We want
to play our part through these initiatives to make big
waves of innovation from Japan that we are about towitness.
It was seven years ago when we acquired the land in KINGSKYFRONT. Due to the Olympics, we had to wait for theright time to commence the construction. We completed it inMarch 2022 at the same time as the opening of theTamagawa Sky Bridge. Our facility started operation inJanuary 2023.

Features of “Cybernics Medical Innovation
Base Tower A”"Laboratories that enable collaboration with otherinstitutions in the building, extensive technical andfinancial support system, and facilities suited for clinicaltrials."（Dr. Sankai) First, all rooms are designed as wet labs forregenerative medicine. Their compartments range from
100㎡ to 800㎡, and those who wish to collaborate canchoose their space according to their business and thenature of their collaboration with us. We have prepared astructure that allows tenant companies to conduct businessactivities efficiently together with our cutting-edge
technologies and our business so that we can maximize
synergies. Also, we have set up spaces for clinical trials
on the 4th floor.
KING SKYFRONT is only 800m away from Haneda
International Airport, and the Tamagawa Sky Bridge's
opening has become even more convenient. I am excited
to create medical innovations with companies that have
similar visions..
In addition, our group has been making investments inbio-related companies. Companies we collaborate with in
this building can also hope for funding opportunities from
our CVC (CEJ Fund). We are the only tech company inthe world that offers such an environment.

（Wearable cyborg HALⓇ）

I want to introduce one of our applications called “Cyvis”
We just finished filing our application for medical devices
in April. Data such as cardiac activities, brain activities,
body temperature, activities, and respiratory status(optional) can be viewed on a single unit of Cyvis. Alldata can be shared in the Cloud. For companies thatdevelop regenerative medicine and drugs, Cyvis will be aperfect application that enables scientific analysis andevaluation by continuous measurement of the data ofpatients for more than one week. It would be an excellent
device for companies that want to measure, collect,analyze, process AI, link, and visualize such data..
Also, people who work in cell culture can add cells andfunctions using our robotic bioreactors so that they willfind the significance and attractiveness of collaboration
with us.

Expectations for KING SKYFRONT～Message from Dr. Sankai～Let's fuse different fields and join us in pioneering thefuture!
(Dr. Sankai) We are a future-pioneering company. We
focus on solving social issues and creating a better future
utilizing a new field of "Cybernics”. However, I think thesame goes for everyone, but there are limits to what wecan do on our own. If we work together regardless of our
backgrounds, it will open up ways to a better future.
Towards creating the future, I have also worked to change
laws and regulations. A good example is that
“Pharmaceutical Affairs Law” has changed to“Pharmaceutical and Medical Device Act.” Thisexperience will be helpful for our challenges in the KINGSKYFRONT. We would have to live up to the expectationof the Kanagawa Prefecture and Kawasaki City officials
who enthusiastically invited us to KING SKYFRONT. I
hope this initiative in the small part of Kanagawa
prefecture will escalate to the next level.
To institutions located at the KING SKYFRONT andcompanies considering moving in, let’s work together andcreate the "Fifth Industrial Revolution" toward therealization of a techno peer support society where peopleand technology coexist and mutually support each other.
Thank you very much, Dr. Sankai.
【For those interested in moving into Cybernics MedicalInnovation Base Tower A】

CYBERDYNE INC.
2-2-1, Gakuen-Minami,Tsukuba, Ibaraki Prefecture 305-0818, Japan
TEL: +81 29-855-3189
https://www.cyberdyne.jp/english/（Head office of CYBERDYNE
where this interview was held. ）Succeeded in identifying a group of cells that plays a leading role in the secretory
function of vascular endothelial growth factor (VEGF) under the ischemic
environment from human mesenchymal/stem cells〜Developed an innovative method for identifying cell groups that contribute to thepharmacological effects of cell-based products〜
On June 2nd, 2023, the research group of Dr. Yoji SATO,Head, Division of Cell-Based Therapeutic Products,
National Institute of Health Sciences (concurrently
serving as part-time researcher at KISTEC), Dr. Takumi
MIURA, Section Chief, Division of Cell-Based
Therapeutic Products, National Institute of HealthSciences, Dr. Jun KAWAI, Full-time Researcher, Next
Generation Life Science Technology Development
Project, KISTEC (concurrently serve as visiting principal
researcher at Laboratory for Large-Scale Biomedical Data
Technology, RIKEN Center for Integrative MedicalSciences), Mr. Hajime KOUNO, research Associate,
Laboratory for Advanced Genomics Circuit, RIKEN
Center for Integrative Medical Sciences (at that time) andDr. Akihiro UMEZAWA, Director, National Center forChild Health and Development, identified a cell
subpopulation that specifically contributes to the abilityof a cell population called human mesenchymal stromal
stem cells (MSCs) to secrete vascular endothelial growth
factor (VEGF) in an ischemic environment.

Details of the research results were published in theBritish scientific journal STEM CELLS Translational
Medicine on 2 June 2023.
Paper title: Single-cell RNA-seq reveals LRRC75Aexpressing cell population involved in VEGF
secretion of multipotent mesenchymal stromal/stem
cells under ischemia
Click here for details
https://www.kistec.jp/aboutus/press/pr20230602/

KUHS published a paper on improvement of the ME-BYO index functions～KUHS will accelerate academic research on ME-BYO～

On May 16th, 2023, Graduate School of HealthInnovation, Kanagawa University of Human Services(KUHS), located in King Skyfront, published a paperon an empirical research project on the ME-BYO
index in Frontiers in Public Health. The index hasbeen promoted by Kanagawa Prefecture, and theschool used the data from the Kanagawa ME-BYO
prospective cohort study. In collaboration with
Kanagawa Prefecture and research institutions therein,
the school has been fostering human resources thatwould revolutionize social system and technology, andhas been engaging in research activities that wouldachieve a healthy longevity society.
The purpose of the research is to contribute to themeasures for pre-symptomatic disease, by collecting
comprehensive data of lifestyle habits from healthypeople, and their data from health checkups andmedical examinations, including their genome
information, turning those data into big data, andconsequently, revealing their disease risk. It has been
carried out in the whole area of Kanagawa Prefecture,with support from around 5,000 residents
Paper title: The ME-BYO index: A development andvalidation project of a novel comprehensive healthindex
https://www.frontiersin.org/articles/10.3389/fpubh.202
3.1142281/full
Click here for details
https://www.kuhs.ac.jp/shi/news/details_02096.html

Why are intractable cancers "intractable"?
According to the National Cancer Center Japan, 26.2% of men and 17.7% of women died from cancer in 2021.
Cancer treatment technology has made great progress compared to the past when it was said that one in threepeople would die from cancer. However, it is also true that some cancers, such as pancreatic cancer, are still
difficult to be cured. Then, why are intractable cancers "intractable"? The reason lies in the soil (cancermicroenvironment) in which the cancer takes root. The worse the prognosis for cancer, the more the immune
system is deterred, creating a more hospitable environment for cancer. There, fibrous material proliferates
abnormally, and blood vessels are crushed, making it inaccessible to immune cells that attack cancer cells. At thesame time, oxygen is reduced, but cancer cells have learned how to survive in hypoxic conditions. It is known
that the degree of hypoxia has a strong correlation with prognosis, and the technology to observe the "cancer
microenvironment" in real-time using MRI and other techniques is very important for formulating treatment
strategies.
References:https://iconm.kawasaki-net.ne.jp/activities_column.html
https://pubs.acs.org/doi/abs/10.1021/acsnano.1c04263

New institutions at Kingsky Front
Two institutions will move into the Kingsky Front.
Jiksak Bioengineering Inc. （Cybernics Medical Innovation
Base Tower A), and YTT Medical Co., Ltd. (TonomachiConnect).
Please welcome them!

For subscription
Keep you updated with the latest news from KINGSKYFRONT
Please apply here for subscription. i-Newsletter comesout quarterly and free subscription.
https://ws.formzu.net/fgen/S11051741/
Date of issue: August 2023
Publisher: TONOMACHI LifeScience Cluster Division
Kawasaki Institute of Industrial Promotion
Mail：pr-ksfcl@kawasaki-net.ne.jp